ロード中...
Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
AIMS: The Medical Research Council OVO5/EORTC 55955 trial showed that patients in remission after first-line therapy for ovarian cancer did not benefit from routine measurement of CA125 during follow-up. Since the presentation of these results, we have counseled patients about the options for follow...
保存先:
| 出版年: | Int J Gynecol Cancer |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499967/ https://ncbi.nlm.nih.gov/pubmed/28333841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000956 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|